Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

Technological innovation and personalized care are transforming Hims & Hers into a proactive health platform. Read why I ...

HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform’s third-quarter forecast ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

Hims & Hers Health, a telehealth platform that sells knockoffs of popular weight loss drugs, sank in after-hours trading ...